High MYC targets scores were also associated with clinically aggressive subtypes, triple-negative breast cancer (TNBC) and HER2-positive breast cancer, compared with ER-positive/HER2-negative tumors (MYC v1 and v2, both p < 0.001). This evidence concerns the gene MYC and breast carcinoma.